Eloxx Pharmaceuticals dismisses Deloitte, appoints Baker Tilly as auditor; no disagreements reported

Eloxx Pharmaceuticals, Inc.

Deloitte & Touche dismissed as independent auditor; Baker Tilly US, LLP engaged for FY 2022, effective July 13, 2022.
No disagreements or reportable events between Eloxx and Deloitte during 2020, 2021, or through July 13, 2022.
Deloitte's audit reports for FY 2020 and 2021 included a going concern doubt about the company's ability to continue.
Deloitte confirmed agreement with the disclosures in a letter filed as Exhibit 16.1; no prior consultations with Baker Tilly.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.